Involvement of the adapter protein CRKL in integrin-mediated adhesion
CRKL, an SH2-SH3-SH3 adapter protein, is one of the major tyrosine phosphoproteins detected in primary leukemic neutrophils from patients with CML. CRKL binds directly to BCR/ABL through its N-terminal SH3 domain, suggesting it may be involved in BCR/ABL signal transduction. However, the biological...
Saved in:
Published in | Oncogene Vol. 18; no. 22; pp. 3343 - 3353 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Basingstoke
Nature Publishing
03.06.1999
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | CRKL, an SH2-SH3-SH3 adapter protein, is one of the major tyrosine phosphoproteins detected in primary leukemic neutrophils from patients with CML. CRKL binds directly to BCR/ABL through its N-terminal SH3 domain, suggesting it may be involved in BCR/ABL signal transduction. However, the biological function of CRKL in either normal or leukemic cells is still largely unknown. In this study, we have examined the effects of overexpressing full length or deletion mutants of CRKL in hematopoietic cell lines. Full length, SH2- and SH3(N)-domain deletion mutants of CRKL were transfected into an interleukin-3-dependent hematopoietic cell line, Ba/F3, and 3-5 individual sublines which stably overexpressed each transgene were obtained [Ba/F-CRKL, Ba/F-CRKL deltaSH2, and Ba/F-CRKL deltaSH3(N)]. The growth properties of these transfected cells in the presence or absence of IL-3 were not different from mock transfected or untransfected Ba/F3 cells. However, Ba/F3 cells overexpressing full length CRKL, but not deletion mutants of CRKL, were found to have an increase in their ability to bind to fibronectin-coated surfaces. Further, expression of full length, but not deltaSH2- or deltaSH3-CRKL deletion mutants, was found to alter cell morphology on fibronectin-coated plates, an effect which was further enhanced by certain kinds of stress stimuli, such as ionizing radiation. Similar results were obtained when CRKL was transiently overexpressed in Ba/F3 cells, and were also obtained in a second IL-3 dependent hematopoietic cell line, 32Dcl3. Adhesion to fibronectin was blocked by anti-beta1 integrin monoclonal antibody, but overexpression of CRKL did not affect surface expression of beta1 integrins, nor did it spontaneously induce expression of the beta1 integrin 'activation' epitope recognized by the 9EG7 monoclonal antibody. These data suggest a role for CRKL in signaling pathways which regulate adhesion to fibronectin. |
---|---|
AbstractList | CRKL, an SH2-SH3-SH3 adapter protein, is one of the major tyrosine phosphoproteins detected in primary leukemic neutrophils from patients with CML. CRKL binds directly to BCR/ABL through its N-terminal SH3 domain, suggesting it may be involved in BCR/ABL signal transduction. However, the biological function of CRKL in either normal or leukemic cells is still largely unknown. In this study, we have examined the effects of overexpressing full length or deletion mutants of CRKL in hematopoietic cell lines. Full length, SH2- and SH3(N)-domain deletion mutants of CRKL were transfected into an interleukin-3-dependent hematopoietic cell line, Ba/F3, and 3-5 individual sublines which stably overexpressed each transgene were obtained [Ba/ F-CRKL, Ba/F-CRKL Delta SH2, and Ba/F-CRKL Delta SH3(N)]. The growth properties of these transfected cells in the presence or absence of IL-3 were not different from mock transfected or untransfected Ba/F3 cells. However, Ba/F3 cells overexpressing full length CRKL, but not deletion mutants of CRKL, were found to have an increase in their ability to bind to fibronectin-coated surfaces. Further, expression of full length, but not Delta SH2- or Delta SH3-CRKL deletion mutants, was found to alter cell morphology on fibronectin-coated plates, an effect which was further enhanced by certain kinds of stress stimuli, such as ionizing radiation. Similar results were obtained when CRKL was transiently overexpressed in Ba/F3 cells, and were also obtained in a second IL-3 dependent hematopoietic cell line, 32Dcl3. Adhesion to fibronectin was blocked by anti- beta 1 integrin monoclonal antibody, but overexpression of CRKL did not affect surface expression of beta 1 integrins, nor did it spontaneously induce expression of the beta 1 integrin 'activation' epitope recognized by the 9EG7 monoclonal antibody. These data suggest a role for CRKL in signaling pathways which regulate adhesion to fibronectin. CRKL, an SH2-SH3-SH3 adapter protein, is one of the major tyrosine phosphoproteins detected in primary leukemic neutrophils from patients with CML. CRKL binds directly to BCR/ABL through its N-terminal SH3 domain, suggesting it may be involved in BCR/ABL signal transduction. However, the biological function of CRKL in either normal or leukemic cells is still largely unknown. In this study, we have examined the effects of overexpressing full length or deletion mutants of CRKL in hematopoietic cell lines. Full length, SH2- and SH3(N)-domain deletion mutants of CRKL were transfected into an interleukin-3-dependent hematopoietic cell line, Ba/F3, and 3 – 5 individual sublines which stably overexpressed each transgene were obtained [Ba/F-CRKL, Ba/F-CRKLΔSH2, and Ba/F-CRKL ΔSH3(N)]. The growth properties of these transfected cells in the presence or absence of IL-3 were not different from mock transfected or untransfected Ba/F3 cells. However, Ba/F3 cells overexpressing full length CRKL, but not deletion mutants of CRKL, were found to have an increase in their ability to bind to fibronectin-coated surfaces. Further, expression of full length, but not ΔSH2- or ΔSH3-CRKL deletion mutants, was found to alter cell morphology on fibronectin-coated plates, an effect which was further enhanced by certain kinds of stress stimuli, such as ionizing radiation. Similar results were obtained when CRKL was transiently overexpressed in Ba/F3 cells, and were also obtained in a second IL-3 dependent hematopoietic cell line, 32Dcl3. Adhesion to fibronectin was blocked by anti-β1 integrin monoclonal antibody, but overexpression of CRKL did not affect surface expression of β1 integrins, nor did it spontaneously induce expression of the β1 integrin `activation' epitope recognized by the 9EG7 monoclonal antibody. These data suggest a role for CRKL in signaling pathways which regulate adhesion to fibronectin. CRKL, an SH2-SH3-SH3 adapter protein, is one of the major tyrosine phosphoproteins detected in primary leukemic neutrophils from patients with CML. CRKL binds directly to BCR/ABL through its N-terminal SH3 domain, suggesting it may be involved in BCR/ABL signal transduction. However, the biological function of CRKL in either normal or leukemic cells is still largely unknown. In this study, we have examined the effects of overexpressing full length or deletion mutants of CRKL in hematopoietic cell lines. Full length, SH2- and SH3(N)-domain deletion mutants of CRKL were transfected into an interleukin-3-dependent hematopoietic cell line, Ba/F3, and 3-5 individual sublines which stably overexpressed each transgene were obtained [Ba/F-CRKL, Ba/F-CRKL deltaSH2, and Ba/F-CRKL deltaSH3(N)]. The growth properties of these transfected cells in the presence or absence of IL-3 were not different from mock transfected or untransfected Ba/F3 cells. However, Ba/F3 cells overexpressing full length CRKL, but not deletion mutants of CRKL, were found to have an increase in their ability to bind to fibronectin-coated surfaces. Further, expression of full length, but not deltaSH2- or deltaSH3-CRKL deletion mutants, was found to alter cell morphology on fibronectin-coated plates, an effect which was further enhanced by certain kinds of stress stimuli, such as ionizing radiation. Similar results were obtained when CRKL was transiently overexpressed in Ba/F3 cells, and were also obtained in a second IL-3 dependent hematopoietic cell line, 32Dcl3. Adhesion to fibronectin was blocked by anti-beta1 integrin monoclonal antibody, but overexpression of CRKL did not affect surface expression of beta1 integrins, nor did it spontaneously induce expression of the beta1 integrin 'activation' epitope recognized by the 9EG7 monoclonal antibody. These data suggest a role for CRKL in signaling pathways which regulate adhesion to fibronectin. |
Author | GRIFFIN, J. D UEMURA, N EWANIUK, D. S SALGIA, R LITTLE, M.-T |
Author_xml | – sequence: 1 givenname: N surname: UEMURA fullname: UEMURA, N organization: Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, Massachusetts, MA 02115, United States – sequence: 2 givenname: R surname: SALGIA fullname: SALGIA, R organization: Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, Massachusetts, MA 02115, United States – sequence: 3 givenname: D. S surname: EWANIUK fullname: EWANIUK, D. S organization: Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, Massachusetts, MA 02115, United States – sequence: 4 givenname: M.-T surname: LITTLE fullname: LITTLE, M.-T organization: Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, Massachusetts, MA 02115, United States – sequence: 5 givenname: J. D surname: GRIFFIN fullname: GRIFFIN, J. D organization: Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, Massachusetts, MA 02115, United States |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1859199$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/10362355$$D View this record in MEDLINE/PubMed |
BookMark | eNqF0UlLAzEUB_AgFbvo1aMMKN6mZplkkqOUumBBED2HTOaNnTJNajIt-O2NtKB48fQuv_fnLWM0cN4BQucETwlm8iaupt7ZKaGYCqmO0IgUpcg5V8UAjbDiOFeU0SEax7jCGJcK0xM0TK2CMs5HaP7odr7bwRpcn_km65eQmdpsegjZJvgeWpfNXp4WWaqt6-E9tC5fQ92aHuoklxBb707RcWO6CGeHOkFvd_PX2UO-eL5_nN0uclsQ1efEME4pJaqqKW4aSSomuGiq0hBb89oQAyBZxerSKgukERyXVFhOFbdSCcMm6Hqfm0b72ELs9bqNFrrOOPDbqIWSWCjF_oUk5RasUAle_oErvw0uLaGTIFSWUsqkpntlg48xQKM3oV2b8KkJ1t9_0HGl0x_04Q-p4eIQu63StX7x_eETuDoAE63pmmCcbeOPk1yRtMgXVGGRZA |
CitedBy_id | crossref_primary_10_1074_jbc_M004627200 crossref_primary_10_3892_ijo_2014_2759 crossref_primary_10_1097_00029330_200703010_00007 crossref_primary_10_1016_j_hoc_2004_03_008 crossref_primary_10_1182_blood_V97_12_3768 crossref_primary_10_1016_S1359_6101_01_00029_6 crossref_primary_10_1182_blood_V95_8_2505 crossref_primary_10_1002_jcp_20694 crossref_primary_10_3389_fimmu_2015_00509 crossref_primary_10_1002_jcp_24412 crossref_primary_10_1182_blood_V99_7_2351 crossref_primary_10_1182_blood_V95_8_2505_008k24_2505_2513 crossref_primary_10_1263_jbb_103_444 crossref_primary_10_1080_15368378_2020_1846555 crossref_primary_10_1186_1478_811X_11_9 crossref_primary_10_1074_jbc_M102924200 crossref_primary_10_1074_jbc_274_53_37525 crossref_primary_10_1182_blood_2001_11_0032 crossref_primary_10_1146_annurev_immunol_22_012703_104649 crossref_primary_10_1002_cyto_a_20424 crossref_primary_10_1007_BF02981955 crossref_primary_10_1182_blood_2003_01_0062 crossref_primary_10_1038_s41392_021_00823_w crossref_primary_10_1074_jbc_M210817200 crossref_primary_10_1189_jlb_71_3_425 |
Cites_doi | 10.1073/pnas.90.19.9051 10.1038/374477a0 10.1074/jbc.270.25.15341 10.1182/blood.V84.9.2912.bloodjournal8492912 10.1101/gad.8.7.783 10.1042/bj3250375 10.1182/blood.V84.6.1731.1731 10.1006/bbrc.1997.7480 10.1128/MCB.18.5.3044 10.1006/excr.1996.3466 10.1074/jbc.270.37.21468 10.1074/jbc.270.49.29145 10.1074/jbc.270.10.5039 10.1128/MCB.12.8.3482 10.1074/jbc.271.41.25198 10.1172/JCI118820 10.1073/pnas.93.26.15174 10.1074/jbc.272.7.4230 10.1074/jbc.270.7.2893 10.1038/332272a0 10.1016/S0021-9258(17)31596-X 10.1002/j.1460-2075.1994.tb06518.x 10.1074/jbc.270.25.15398 10.2307/3578372 10.1007/978-1-4615-2994-1_14 10.1074/jbc.272.22.14320 10.1016/0092-8674(89)90985-9 10.1073/pnas.94.9.4463 10.1038/sj.leu.2400590 10.1002/j.1460-2075.1994.tb06684.x 10.1074/jbc.272.35.22215 10.1074/jbc.272.15.10248 10.1093/nar/18.17.5322 10.1128/MCB.16.4.1770 10.1128/MCB.13.8.4648 10.1182/blood.V87.1.73.73 10.1182/blood.V89.9.3166 10.1073/pnas.92.23.10678 10.1073/pnas.91.8.3443 10.1083/jcb.140.4.961 10.1002/bies.950161108 10.1074/jbc.271.38.23255 10.1002/j.1460-2075.1991.tb07693.x 10.1038/sj.onc.1200885 10.1128/MCB.18.9.5082 10.1016/S0021-9258(19)50057-6 10.1016/S0960-9822(95)00060-1 |
ContentType | Journal Article |
Copyright | 1999 INIST-CNRS Macmillan Publishers Limited 1999. |
Copyright_xml | – notice: 1999 INIST-CNRS – notice: Macmillan Publishers Limited 1999. |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7TM 7TO 7U9 8FD FR3 H94 K9. P64 RC3 7X8 |
DOI | 10.1038/sj.onc.1202689 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Genetics Abstracts Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts Technology Research Database Nucleic Acids Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitleList | Oncogenes and Growth Factors Abstracts Genetics Abstracts MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Biology |
EISSN | 1476-5594 |
EndPage | 3353 |
ExternalDocumentID | 10_1038_sj_onc_1202689 10362355 1859199 |
Genre | Research Support, U.S. Gov't, P.H.S Journal Article |
GrantInformation_xml | – fundername: NIDDK NIH HHS grantid: DK560654 – fundername: NCI NIH HHS grantid: CA36167 |
GroupedDBID | --- -Q- .55 .GJ 08R 0R~ 123 29N 2WC 36B 39C 3O- 3V. 4.4 406 53G 5RE 70F 7X7 88A 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8R4 8R5 AADWK AANZL AAPBV AATNV AAUGY AAWBL AAYFA AAYJO AAZLF ABAWZ ABDBF ABEFU ABGIJ ABLJU ABPTK ABUWG ACBMV ACBRV ACBYP ACGFO ACGFS ACIGE ACKTT ACMJI ACPRK ACRQY ACTTH ACVWB ADBBV ADFRT ADHDB ADMDM ADQMX ADYYL AEDAW AEFTE AEJRE AENEX AEVLU AEXYK AFFNX AFKRA AFNRJ AFSHS AGEZK AGGBP AGHAI AHMBA AHSBF AILAN AJCLW AJDOV AJRNO ALFFA ALMA_UNASSIGNED_HOLDINGS AMRJV AMYLF ASPBG AVWKF AXYYD AZFZN AZQEC B0M BAWUL BBNVY BENPR BHPHI BKKNO BPHCQ BVXVI CAG CCPQU COF CS3 DIK DNIVK DPUIP DU5 DWQXO E3Z EAD EAP EBC EBD EBLON EBS EE. EIOEI EJD EMB EMK EMOBN EPL ESX F5P FDQFY FEDTE FERAY FIZPM FRP FSGXE FYUFA GNUQQ GUQSH HCIFZ HZ~ IAO IHR INH INR IQODW ITC IWAJR JSO JZLTJ KQ8 L7B LK8 M0L M1P M2O M7P N9A NAO NQJWS NXXTH NYICJ O9- OK1 OVD P2P PQQKQ PROAC PSQYO Q2X RNS RNT RNTTT SNX SNYQT SOHCF SRMVM SV3 SWTZT TAOOD TBHMF TDRGL TEORI TR2 TSG TUS UDS UKHRP W2D WH7 X7M ZA5 ZXP ~8M AAYZH ABAKF ABJNI ABZZP ACAOD ACZOJ AEMSY AFBBN AGQEE ALIPV CGR CUY CVF ECM EIF HVGLF NPM AAYXX CITATION 7TM 7TO 7U9 8FD FR3 H94 K9. P64 RC3 7X8 |
ID | FETCH-LOGICAL-c419t-1a3522219bd20ff81b3656fb7a1cd5da1aee83b3d7c9ce1f650726c5295c896a3 |
ISSN | 0950-9232 |
IngestDate | Fri Oct 25 01:50:17 EDT 2024 Fri Oct 25 23:55:09 EDT 2024 Thu Oct 10 19:20:30 EDT 2024 Thu Sep 26 19:16:53 EDT 2024 Tue Oct 15 23:17:18 EDT 2024 Sun Oct 29 17:07:24 EDT 2023 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 22 |
Keywords | Rodentia SH3 Domain Adhesion SH2 Domain Signal transduction Vertebrata Mammalia Integrin Cell line Mouse C-Onc gene Extracellular matrix Mutation Fusion protein |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c419t-1a3522219bd20ff81b3656fb7a1cd5da1aee83b3d7c9ce1f650726c5295c896a3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
OpenAccessLink | https://doi.org/10.1038/sj.onc.1202689 |
PMID | 10362355 |
PQID | 2641287888 |
PQPubID | 36330 |
PageCount | 11 |
ParticipantIDs | proquest_miscellaneous_69806993 proquest_miscellaneous_17264349 proquest_journals_2641287888 crossref_primary_10_1038_sj_onc_1202689 pubmed_primary_10362355 pascalfrancis_primary_1859199 |
PublicationCentury | 1900 |
PublicationDate | 1999-06-03 |
PublicationDateYYYYMMDD | 1999-06-03 |
PublicationDate_xml | – month: 06 year: 1999 text: 1999-06-03 day: 03 |
PublicationDecade | 1990 |
PublicationPlace | Basingstoke |
PublicationPlace_xml | – name: Basingstoke – name: England – name: New York |
PublicationTitle | Oncogene |
PublicationTitleAlternate | Oncogene |
PublicationYear | 1999 |
Publisher | Nature Publishing Nature Publishing Group |
Publisher_xml | – name: Nature Publishing – name: Nature Publishing Group |
References | BF1202689_CR38 BF1202689_CR37 BF1202689_CR36 BF1202689_CR35 BF1202689_CR39 BF1202689_CR41 BF1202689_CR40 BF1202689_CR45 BF1202689_CR44 BF1202689_CR43 BF1202689_CR42 BF1202689_CR6 BF1202689_CR7 BF1202689_CR8 BF1202689_CR9 BF1202689_CR49 BF1202689_CR48 BF1202689_CR47 BF1202689_CR1 BF1202689_CR46 BF1202689_CR2 BF1202689_CR3 BF1202689_CR4 BF1202689_CR5 BF1202689_CR52 BF1202689_CR51 BF1202689_CR50 BF1202689_CR12 BF1202689_CR11 BF1202689_CR55 BF1202689_CR10 BF1202689_CR54 BF1202689_CR53 BF1202689_CR16 BF1202689_CR15 BF1202689_CR14 BF1202689_CR13 BF1202689_CR19 BF1202689_CR18 BF1202689_CR17 BF1202689_CR23 BF1202689_CR22 BF1202689_CR21 BF1202689_CR20 BF1202689_CR27 BF1202689_CR26 BF1202689_CR25 BF1202689_CR24 BF1202689_CR29 BF1202689_CR28 BF1202689_CR30 BF1202689_CR34 BF1202689_CR33 BF1202689_CR32 BF1202689_CR31 |
References_xml | – ident: BF1202689_CR19 doi: 10.1073/pnas.90.19.9051 – ident: BF1202689_CR36 doi: 10.1038/374477a0 – ident: BF1202689_CR52 – ident: BF1202689_CR46 doi: 10.1074/jbc.270.25.15341 – ident: BF1202689_CR28 doi: 10.1182/blood.V84.9.2912.bloodjournal8492912 – ident: BF1202689_CR35 doi: 10.1101/gad.8.7.783 – ident: BF1202689_CR5 doi: 10.1042/bj3250375 – ident: BF1202689_CR51 doi: 10.1182/blood.V84.6.1731.1731 – ident: BF1202689_CR8 doi: 10.1006/bbrc.1997.7480 – ident: BF1202689_CR1 doi: 10.1128/MCB.18.5.3044 – ident: BF1202689_CR34 doi: 10.1006/excr.1996.3466 – ident: BF1202689_CR9 doi: 10.1074/jbc.270.37.21468 – ident: BF1202689_CR41 doi: 10.1074/jbc.270.49.29145 – ident: BF1202689_CR38 doi: 10.1074/jbc.270.10.5039 – ident: BF1202689_CR42 – ident: BF1202689_CR23 doi: 10.1128/MCB.12.8.3482 – ident: BF1202689_CR39 doi: 10.1074/jbc.271.41.25198 – ident: BF1202689_CR4 doi: 10.1172/JCI118820 – ident: BF1202689_CR20 doi: 10.1073/pnas.93.26.15174 – ident: BF1202689_CR22 doi: 10.1074/jbc.272.7.4230 – ident: BF1202689_CR45 doi: 10.1074/jbc.270.7.2893 – ident: BF1202689_CR24 – ident: BF1202689_CR49 – ident: BF1202689_CR25 doi: 10.1038/332272a0 – ident: BF1202689_CR30 doi: 10.1016/S0021-9258(17)31596-X – ident: BF1202689_CR11 doi: 10.1002/j.1460-2075.1994.tb06518.x – ident: BF1202689_CR29 doi: 10.1074/jbc.270.25.15398 – ident: BF1202689_CR31 doi: 10.2307/3578372 – ident: BF1202689_CR55 doi: 10.1007/978-1-4615-2994-1_14 – ident: BF1202689_CR44 doi: 10.1074/jbc.272.22.14320 – ident: BF1202689_CR17 doi: 10.1016/0092-8674(89)90985-9 – ident: BF1202689_CR32 doi: 10.1073/pnas.94.9.4463 – ident: BF1202689_CR54 doi: 10.1038/sj.leu.2400590 – ident: BF1202689_CR37 doi: 10.1002/j.1460-2075.1994.tb06684.x – ident: BF1202689_CR2 – ident: BF1202689_CR14 doi: 10.1074/jbc.272.35.22215 – ident: BF1202689_CR12 – ident: BF1202689_CR43 doi: 10.1074/jbc.272.15.10248 – ident: BF1202689_CR27 doi: 10.1093/nar/18.17.5322 – ident: BF1202689_CR13 doi: 10.1128/MCB.16.4.1770 – ident: BF1202689_CR7 doi: 10.1128/MCB.13.8.4648 – ident: BF1202689_CR15 doi: 10.1182/blood.V87.1.73.73 – ident: BF1202689_CR40 – ident: BF1202689_CR3 doi: 10.1182/blood.V89.9.3166 – ident: BF1202689_CR33 doi: 10.1073/pnas.92.23.10678 – ident: BF1202689_CR53 – ident: BF1202689_CR50 doi: 10.1073/pnas.91.8.3443 – ident: BF1202689_CR18 doi: 10.1083/jcb.140.4.961 – ident: BF1202689_CR21 doi: 10.1002/bies.950161108 – ident: BF1202689_CR47 doi: 10.1074/jbc.271.38.23255 – ident: BF1202689_CR16 doi: 10.1002/j.1460-2075.1991.tb07693.x – ident: BF1202689_CR10 doi: 10.1038/sj.onc.1200885 – ident: BF1202689_CR48 doi: 10.1128/MCB.18.9.5082 – ident: BF1202689_CR6 doi: 10.1016/S0021-9258(19)50057-6 – ident: BF1202689_CR26 doi: 10.1016/S0960-9822(95)00060-1 |
SSID | ssj0007902 |
Score | 1.7705201 |
Snippet | CRKL, an SH2-SH3-SH3 adapter protein, is one of the major tyrosine phosphoproteins detected in primary leukemic neutrophils from patients with CML. CRKL binds... |
SourceID | proquest crossref pubmed pascalfrancis |
SourceType | Aggregation Database Index Database |
StartPage | 3343 |
SubjectTerms | Abl gene Adapter proteins Adaptor Proteins, Signal Transducing Animals BCR gene BCR protein Biological and medical sciences Cell Adhesion - physiology Cell interactions, adhesion Cell Line Cell lines Cytology Deletion mutant Epitopes Extracellular Matrix Proteins - metabolism Fibronectin Fibronectins - metabolism Fundamental and applied biological sciences. Psychology Hematopoietic Stem Cells - cytology Hematopoietic Stem Cells - metabolism Integrins Interleukin 3 Interleukin-3 - metabolism Ionizing radiation Leukemia Leukocytes (neutrophilic) Mice Molecular and cellular biology Monoclonal antibodies Mutants Mutation Nuclear Proteins - genetics Nuclear Proteins - metabolism Phosphoproteins Recombinant Proteins - genetics Recombinant Proteins - metabolism Signal Transduction Tyrosine |
Title | Involvement of the adapter protein CRKL in integrin-mediated adhesion |
URI | https://www.ncbi.nlm.nih.gov/pubmed/10362355 https://www.proquest.com/docview/2641287888 https://search.proquest.com/docview/17264349 https://search.proquest.com/docview/69806993 |
Volume | 18 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF5BEVAJIQiFBlrwAYmTi-31a4-opGppaCWUSLmt1vugqcCOsC0Ev57Zh51YJeJxcSLbcayZ2dlvd2a-Qeg1YFTJWRH7iUiZH8PRJyxJfKW73hdFkBJh2D4v0tN5_GGRLNYt60x1SVMc8Z-_rSv5H63COdCrrpL9B832D4UT8B30C0fQMBz_SsdnJTgXQ_jddLF-JthK8x4a_gVd0ffpfKr3NCwtxLL0TamIhplMXMm604qDp5clr-DfemXP5dfWNCLaiNiwL59tgm0fI5p8Z-WyNW71_XordbrU9Mhmw9VlYgtXbUdMEhQe7BIGPmDALQ6z7aqKnfvD2HIuuakUY0sEfMNNW1L2-vqoAicYRrAOtH2EhnzYF5f0ZD6d0tlkMbuN7kTgSkwg_uy8n2szm1Xav2ZHy4nzt8OnD2DHgxWrYQQo27pk-9rCYIzZI_TQLQ68d1bTj9EtWY7QXdsu9McI3T_uuvON0L2PLiniCZpsmIFXKQ_MwHNm4Dkz8LQZePB5wwy8zgz20PxkMjs-9V13DJ_HIWn8kGnsDBNOIaJAKVh-YMDmqshYyEUiWMikzHGBRcYJl6ECKJ5FKdeBXZ6TlOGnaKesSrmPPFi1CpWDsy9YEseK5ykXOMIsFGkgkywYozed8OjKkqBQk7yAc1pfUxAzdWIeo8OBbNe3a55EAtcPOllTN5BqCpgcUJLeixmjV_1lkKeOXbFSVm1NAWcDdo7J9jtSkoNnIXiMnlkdbrwqoDTA1c__-NsXaHc9Cg7QTvOtlYcAOpvipbG7X2AOgT4 |
link.rule.ids | 315,783,787,27936,27937 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Involvement+of+the+adapter+protein+CRKL+in+integrin-mediated+adhesion&rft.jtitle=Oncogene&rft.au=Uemura%2C+N&rft.au=Salgia%2C+R&rft.au=Ewaniuk%2C+D+S&rft.au=Little%2C+M+T&rft.date=1999-06-03&rft.issn=0950-9232&rft.volume=18&rft.issue=22&rft.spage=3343&rft.epage=3353&rft_id=info:doi/10.1038%2Fsj.onc.1202689&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0950-9232&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0950-9232&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0950-9232&client=summon |